BioSpace News Archive

Statera Biopharma, Inc. announced that, by decision dated October 26, 2022, a Nasdaq Hearings Panel granted the Company’s request for continued listing on The Nasdaq Capital Market, subject to the Company’s satisfaction of certain interim milestones and, ultimately, the Company’s compliance with all applicable criteria for continued listing on Nasdaq, including the $1.00 bid price and $2.5 million stockholders’ equity requirements, by January 31, 2023.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2022 financial results after the U.S. financial markets close on Thursday, November 3, 2022.

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and six months ended September 30, 2022.

Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, notes its partner Neurocrine Biosciences Inc. (“Neurocrine”) announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound NBI-1117568 in adults with schizophrenia.

SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.

According to Nova one advisor, the global Cancer Diagnostics market size was valued at USD 160.9 billion in 2021 and is predicted to hit USD 293.8 billion by 2030 with a registered CAGR of 6.90% during the forecast period 2022 to 2030.

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, announced plans to invest $59 million to significantly expand its laboratory operations in Highland Heights, Kentucky, helping customers deliver life-changing medicines to patients.

LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2022 results, announced a $0.125/share quarterly dividend and provided guidance.